Registered title, quoted from ClinicalTrials.gov
Yiqi Fumai Lyophilized Injection for Chronic Heart Failure Caused by Coronary Heart Disease
An open trial on coronary heart disease, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 2 hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 2
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Study siteFirst Affiliated Hospital of Henan University of Chinese Medicine河南中医药大学第一附属医院ZhengzhouHospital page
- Study siteGuangdong Provincial Hospital of Chinese Medicine广东省中医院GuangzhouHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07803471, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 4
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (4 points)Hide the checklist
40 years to 80 years; sex: all
Registered eligibility fields
A documented diagnosis of chronic heart failure for at least 3 months, or verifiable persistent heart-failure treatment with structural or functional cardiac abnormality; and stable chronic heart failure with reduced ejection fraction at Day 0, defined by LVEF of 40% or less, NT-proBNP of at least 450 pg/mL, and NYHA class II or III.
Inclusion criterion 4
Confirmed coronary heart disease or chronic coronary syndrome according to the protocol-defined criteria, supported by at least one verifiable item such as prior myocardial infarction, prior PCI or CABG, at least 50% stenosis in a major epicardial coronary artery on angiography or coronary CT angiography, FFR of 0.80 or less, iFR of 0.89 or less, or imaging evidence of prior ischemic infarction or scar with corresponding coronary atherosclerosis.
Inclusion criterion 2
For women of childbearing potential, a negative urine or serum pregnancy test during screening; equivocal results or delayed menstruation require repeat testing.
Inclusion criterion 9
Pregnancy or breastfeeding.
Exclusion criterion 11
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; earlier treatment; day-to-day activity level; blood tests: counts, liver and kidney function; other conditions the trial excludes.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07803471, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Age 40 to 80 years, inclusive, of any sex.
- Confirmed coronary heart disease or chronic coronary syndrome according to the protocol-defined criteria, supported by at least one verifiable item such as prior myocardial infarction, prior PCI or CABG, at least 50% stenosis in a major epicardial coronary artery on angiography or coronary CT angiography, FFR of 0.80 or less, iFR of 0.89 or less, or imaging evidence of prior ischemic infarction or scar with corresponding coronary atherosclerosis.
- Heart failure judged to be caused primarily by coronary heart disease, with objective evidence supporting an ischemic cause and no more likely major nonischemic cause.
- A documented diagnosis of chronic heart failure for at least 3 months, or verifiable persistent heart-failure treatment with structural or functional cardiac abnormality; and stable chronic heart failure with reduced ejection fraction at Day 0, defined by LVEF of 40% or less, NT-proBNP of at least 450 pg/mL, and NYHA class II or III.
- Clinical stability at Day 0: no initiation or intensification of intravenous inotropes, vasoactive drugs, mechanical ventilation, mechanical circulatory support, or ultrafiltration within the previous 72 hours; no increase in the daily dose of intravenous loop diuretic within the previous 24 hours; no acute pulmonary edema, worsening resting hypoxemia, or hypoperfusion; no clinically significant progressive deterioration in blood pressure or renal function; and core guideline-directed therapies generally stable for at least 2 weeks. A patient with acute decompensated heart failure during the current hospitalization may not later transition into this study.
- Qi and Yin deficiency syndrome according to the protocol-defined traditional Chinese medicine criteria, requiring qualifying manifestations of both Qi deficiency and Yin deficiency, at least one secondary symptom, and compatible tongue and pulse findings.
- The participant or legally authorized representative can understand the study, participates voluntarily, and signs the informed consent form before any study-specific procedure.
- Able to complete efficacy, safety, quality-of-life, cost, and biospecimen assessments required by the protocol.
- For women of childbearing potential, a negative urine or serum pregnancy test during screening; equivocal results or delayed menstruation require repeat testing.
Exclusion Criteria:
- Acute heart failure, acute decompensation of chronic heart failure, cardiogenic shock, malignant arrhythmia, acute respiratory failure, acute pulmonary edema, need for mechanical ventilation or mechanical circulatory support, or another critical condition requiring immediate rescue treatment.
- Acute coronary syndrome or acute myocardial infarction within 1 month before enrollment if the investigator determines that it will materially affect efficacy, safety, or omics assessments.
- PCI or CABG within 3 months before screening; CRT implantation or upgrade within 6 months before screening; or a definite plan for PCI, CABG, or CRT implantation or upgrade within the next 6 months. Prior CRT is not an absolute exclusion if it was performed at least 6 months earlier, device settings and clinical status are stable, and no major upgrade or parameter change is planned.
- NYHA class IV, clinical instability, or inability to safely complete the short-term study procedures.
- Heart failure caused primarily by severe valvular heart disease, primary cardiomyopathy, congenital heart disease, pericardial disease, cor pulmonale, severe pulmonary hypertension, thyroid dysfunction, severe anemia, infective endocarditis, or another noncoronary cause.
- Severe hepatic, renal, or hematologic disease, including ALT or AST greater than 3 times the upper limit of normal, eGFR less than 30 mL/min/1.73 m2, dialysis, severe anemia, or another condition judged unsuitable by the investigator.
- Markedly uncontrolled glucose metabolism: screening HbA1c of at least 9.0%; or confirmed fasting plasma glucose of at least 13.9 mmol/L after excluding acute infection, stress, and short-term glucocorticoid effects; or diabetic ketoacidosis, hyperosmolar hyperglycemic state, or another condition requiring urgent intensive glucose-lowering treatment. A single elevated random glucose value alone is not sufficient for exclusion.
- Markedly uncontrolled blood pressure or hypotension risk: systolic blood pressure of at least 180 mmHg, diastolic blood pressure of at least 110 mmHg, systolic blood pressure below 90 mmHg, or persistently repeated diastolic blood pressure below 50 mmHg accompanied by dizziness, syncope, oliguria, cold extremities, hypoperfusion, or symptomatic hypotension.
- Severe intracerebral hemorrhage, severe sequelae of cerebral infarction, severe cognitive impairment, psychiatric disorder, aphasia, or another condition that interferes with questionnaire assessment or follow-up data collection.
- Active malignancy, severe infection, active autoimmune disease, or expected survival of less than 6 months.
- Pregnancy or breastfeeding.
- Known allergy to Yiqi Fumai lyophilized injection, red ginseng, Ophiopogon japonicus, Schisandra chinensis, or any excipient; or a prior serious adverse reaction to a similar product.
- Participation in another clinical study that, in the investigator's judgment, may affect efficacy, safety, adherence, or economic evaluation in this study.
- Current use, with planned continuation during the study, or inability to discontinue, of a Qi-tonifying and Yin-nourishing Chinese herbal decoction or proprietary Chinese medicine with effects overlapping those of the study drug.
- Any other condition that the investigator considers unsuitable for participation.
Quoted from ClinicalTrials.gov, NCT07803471, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07803471, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.